Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro.
Fasano A, Noriega FR, Maneval DR Jr, Chanasongcram S, Russell R, Guandalini S, Levine MM. Fasano A, et al. J Clin Invest. 1995 Jun;95(6):2853-61. doi: 10.1172/JCI117991. J Clin Invest. 1995. PMID: 7769126 Free PMC article.
Attenuated Salmonella typhi and Shigella as live oral vaccines and as live vectors.
Levine MM, Galen J, Barry E, Noriega F, Tacket C, Sztein M, Chatfield S, Dougan G, Losonsky G, Kotloff K. Levine MM, et al. Behring Inst Mitt. 1997 Feb;(98):120-3. Behring Inst Mitt. 1997. PMID: 9382732 Review. No abstract available.
Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains.
Nataro JP, Seriwatana J, Fasano A, Maneval DR, Guers LD, Noriega F, Dubovsky F, Levine MM, Morris JG Jr. Nataro JP, et al. Infect Immun. 1995 Dec;63(12):4721-8. doi: 10.1128/IAI.63.12.4721-4728.1995. Infect Immun. 1995. PMID: 7591128 Free PMC article.
Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.
Kotloff KL, Noriega F, Losonsky GA, Sztein MB, Wasserman SS, Nataro JP, Levine MM. Kotloff KL, et al. Infect Immun. 1996 Nov;64(11):4542-8. doi: 10.1128/IAI.64.11.4542-4548.1996. Infect Immun. 1996. PMID: 8890204 Free PMC article. Clinical Trial.
Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans.
Gonzalez C, Hone D, Noriega FR, Tacket CO, Davis JR, Losonsky G, Nataro JP, Hoffman S, Malik A, Nardin E, Sztein MB, Heppner DG, Fouts TR, Isibasi A, Levine MM, et al. Gonzalez C, et al. J Infect Dis. 1994 Apr;169(4):927-31. doi: 10.1093/infdis/169.4.927. J Infect Dis. 1994. PMID: 8133113 Clinical Trial.
DeltaguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin.
Anderson RJ, Pasetti MF, Sztein MB, Levine MM, Noriega FR. Anderson RJ, et al. Among authors: noriega fr. Vaccine. 2000 Apr 28;18(21):2193-202. doi: 10.1016/s0264-410x(00)00025-6. Vaccine. 2000. PMID: 10717338
Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.
Kotloff KL, Noriega FR, Samandari T, Sztein MB, Losonsky GA, Nataro JP, Picking WD, Barry EM, Levine MM. Kotloff KL, et al. Among authors: noriega fr. Infect Immun. 2000 Mar;68(3):1034-9. doi: 10.1128/iai.68.3.1034-1039.2000. Infect Immun. 2000. PMID: 10678904 Free PMC article.
Strategy for cross-protection among Shigella flexneri serotypes.
Noriega FR, Liao FM, Maneval DR, Ren S, Formal SB, Levine MM. Noriega FR, et al. Infect Immun. 1999 Feb;67(2):782-8. doi: 10.1128/IAI.67.2.782-788.1999. Infect Immun. 1999. PMID: 9916090 Free PMC article.
18 results
Jump to page
Feedback